Study of a new drug for moderate to severe COPD in smokers
Part of Lungs & breathing clinical trials.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You have moderate to very severe COPD
- You are a current or former smoker
- You are using inhalers (like triple or dual therapy) for COPD
- You do not have asthma or other lung diseases
- You have not had a recent COPD flare-up or lung infection (in the last 4 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
This trial tests a new medicine to see how the body handles it and whether it is safe. It is for healthy people, not for treating a disease, and helps researchers decide if the drug can move to the next stage of testing.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
This study is testing whether an investigational drug called GSK5784283 can improve asthma control compared to a placebo. It is for people with uncontrolled asthma who are already on standard daily asthma medications.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.